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ABSTRACT 
Inflammatory bowel disease (IBD) describes chronic relapsing remitting inflammation of the 
gastrointestinal tract including ulcerative colitis and Crohn’s disease. The prevalence of IBD is 
rising across the globe. Despite a growing therapeutic arsenal, current medical treatments 
are not universally effective, do not induce lasting remission in all, or are accompanied by 
short and long-term adverse effects. Therefore, there is a clinical need for novel therapeutic 
strategies for IBD. Current treatments for IBD mainly manipulate the immune system for 
therapeutic gain by inhibiting pro-inflammatory activity. There is a robust endogenous 
immunoregulatory capacity within the repertoire of both innate and adaptive immune 
responses. An alternative treatment strategy for IBD is to hijack and bolster this endogenous 
capability for therapeutic gain. This review explores this hypothesis and presents current 
evidence for this therapeutic direction in immune cell function, cytokine biology, and 
alternative mechanisms of immunoregulation such as microRNA, oligonucleotides and the 
endocannabinoid system. 
 
 
Keywords: Inflammatory Bowel Disease, immunoregulation, cytokine, ulcerative colitis, 
Crohn’s disease, treatment. 
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INTRODUCTION  
Inflammatory bowel disease (IBD) describes relapsing, remitting chronic inflammation 
of the gastrointestinal tract. The main phenotypes are ulcerative colitis and Crohn’s disease. 
The prevalence of IBD remains highest in Europe and the United States, and continues to rise 
across the globe.1 The aetiology of IBD is complex and involves dynamic interplay between 
genetics, the immune system and environmental exposures including intestinal microbial 
dysbiosis.1 Advances in IBD research has widened therapeutic opportunities and impacted on 
disease treatment and natural progression.  
Current treatments for IBD aim to inhibit pro-inflammatory immune responses, 
targeting both inflammatory cells and cytokines. There are several agents available to achieve 
this including steroids, thiopurines and biologic anti-tumour necrosis factor (TNF) and anti-
integrin therapies. However, not all patients are responsive to these drugs.2 There are 
emerging novel biologics for IBD for example anti-p40 biologic targeting interleukin (IL)-12 
and IL-23 offering multiple cytokine inhibition. Trials have suggested that these new biologics 
are not globally effective across all IBD patient cohorts.3 Furthermore, currently available 
drugs are associated with serious adverse side effects including susceptibility to infection, 
bone marrow suppression, liver dysfunction and increased risk of malignancy.2 Therefore, 
there is a clinical need for newer, safer treatments for IBD.  
There is a robust endogenous immunoregulatory capacity within the repertoire of 
both innate and adaptive immune responses. An alternative treatment strategy for IBD could 
be to hijack and bolster this endogenous capability for therapeutic gain. This review explores 
this hypothesis and presents current evidence for this therapeutic direction. 
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IMMUNE CELL POPULATIONS 
Regulatory T-Cells 
Regulatory T cells (Tregs) are vital contributors to immune homeostasis. There are 
various subsets of Tregs, including IL-10 producing Tr1 cells, CD4+CD25+Foxp3+ or CD4+CD25-
Foxp3+ Tregs and IL-35 producing T-cells.4 Foxp3+ Tregs include thymic-derived Tregs (for 
central tolerance) and peripheral induced CD4+ T-cells (for local tolerance). Thymic-derived 
Tregs naturally express Foxp3 and peripheral CD4+ T-cells can upregulate Foxp3 under certain 
circumstances, such as in response to pro-inflammatory cytokines.4 
In the intestine, Tregs secrete anti-inflammatory cytokines and modulate T-cell 
function to exert immunosuppressive activity. Tregs also downregulate co-stimulatory 
molecules on antigen presenting cells to maintain immune tolerance through expression of 
T-cell receptors specific for enteric flora and dietary antigens. Imbalance between Treg and 
effector T-cell populations is an important mechanism underlying IBD pathogenesis.4,5 
IBD patients in remission express more CD4+CD25high and Foxp3+ Tregs in their 
peripheral bloodstream, compared to patients with active disease.6 These cells maintain their 
suppressive role, determined by proliferative suppression of CD4+C25- T-cells, correlated with 
disease activity and CRP levels.6,7 In the gastrointestinal mucosa, patients with IBD express 
more CD4+CD25high and Foxp3+ Tregs compared to non-inflamed mucosa.6 Compared to 
normal mucosa, patients with ulcerative colitis express more Foxp3+ Tregs in their inflamed 
and non-inflamed mucosa. Expression appears predominantly in the lamina propria.8 In 
mesenteric lymph nodes of patients with ulcerative colitis, CD4+CD25+ cells express Foxp3 and 
suppress the proliferation of autologous CD4+CD25+ cells.8 Overall, IBD is associated with 
reduced peripheral and modestly increased Tregs in the colonic mucosa. Whilst many 
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questions remain unanswered in Treg biology, the question relevant to this review is potential 
promotion of the potent anti-inflammatory activity of Tregs as a therapeutic strategy for IBD.  
Promotion of the anti-inflammatory functions of Tregs can be achieved indirectly 
through multiple diverse actions and there is a broad base of investigative work in the 
literature to this effect. Intestinal dysbiosis plays a pivotal role in IBD pathogenesis.1 Indeed, 
bacterial components are important for Treg function, for example, spore-forming clusters IV 
and XIVa of the Clostridium genus promote Treg accumulation in the colons of mice.9 Hence, 
manipulation of intestinal bacteria may bolster the mucosal Treg population and promote a 
tolerogenic microenvironment. Butyrate, an energy source for colonocytes, can promote Treg 
activity and suppress serum and colonic mucosal levels of IL-17, leading to amelioration of 
TBNS-induced colitis in rats.10 Lactoferrin, an endogenous pleiotropic protein secreted at 
mucosal sites, can modulate inflammation by shifting the phenotype of CD4+ T-cells away 
from Th17 and towards Tregs.11  
Oral immune therapies introduce low dose antigens to the gut to manipulate the local 
host immune system and this strategy can preferentially expand mucosal Treg populations to 
promote oral antigenic tolerance. There have been numerous promising pre-clinical studies 
and a few clinical trials that have suggested benefit in IBD, as comprehensively reviewed 
elsewhere.12 An example of this strategy is the oral administration of non-absorbable 
autologous colonic protein-derived antigens (Alequel). This ameliorated immune-mediated 
colitis in mice and induced remission in human Crohn’s disease in phase I and II trials.13–16 The 
mechanism is not fully understood but likely involves promotion of Treg cells, upregulation of 
IL-10, and an altered CD4+/CD8+ ratio.  
Another example of enhancing Treg responses as part of a wider immunosuppressive 
repertoire is the use of anti-CD3 monoclonal antibody biologics, such as otelixizumab. The 
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mechanism of action is multifactorial, including inhibition of antigenic stimulation by 
internalisation of the CD3/TCR complex inhibiting antigenic stimulation, promotion of 
effector T cell apoptosis, and amplification of TGFβ signalling to create a tolerogenic 
microenvironment via promotion of Treg and tolerogenic dendritic cell populations.17 These 
novel biologics have been assessed in different autoimmune conditions, with particular focus 
in Type 1 diabetes mellitus. In a murine model of IBD, use of an anti-CD3 antibody attenuated 
T cell transfer-induced enterocolitis.18 These agents have been trialled in humans in both 
acute severe ulcerative colitis19–21 and Crohns disease.22 Although initial small studies were 
optimistic, larger studies showed this agent was not effective in acute severe UC and was 
associated with an unacceptable toxicity profile. Different biologics to the CD3 receptor are 
in clinical development and emerging and this is likely to continue as a future area of 
therapeutic development in IBD.  
Can we use regulatory T cells directly as a therapy? Adoptive transfer of autologous 
Tregs has emerged as another promising therapeutic avenue in IBD. This strategy of 
enhancing endogenous cell based immunoregulation has been shown to be effective in pre-
clinical models.23–28 For example, adoptive transfer of CD4+CD25+ Tregs in a T cell transfer 
model of murine IBD significantly reversed clinical and histological markers of colitis by 
migrating to the intestine, proliferating and directly interacting with effector T cells.26 
Challenges in application of this treatment to humans include in vitro cell expansion to 
achieve an effective dose, potential plasticity of the expanded cells towards a pro-
inflammatory phenotype, and ensuring an effective and consistent homing to the GI tract on 
infusion. Canavan and colleagues published data to show successful isolation, 
characterisation and expansion of a specific Treg population deemed suitable for this 
Can we target endogenous anti-inflammatory responses as a therapeutic strategy for 
inflammatory bowel disease? 
8 
 
application.29 A clinical trial (TRIBUTE) to assess these cells in human Crohn’s disease is in the 
early stages of recruitment (UK Trials Gateway; ISRCTN97547683).  
Another group reported data from a 12-week, open-label, multi-centre phase 1/2a 
clinical trial to investigate the safety and efficacy of adoptive transfer of a different Treg 
subset, namely intravenous ovalbumin-specific Tr1 Tregs in humans, expanded from 
peripheral mononuclear blood cells, in refractory Crohn’s disease.30 This treatment was 
efficacious in 40% of patients, dose-dependent (lower dose was more efficacious) and was 
well tolerated with few adverse effects. A larger multi-centre international randomised 
placebo controlled study of this antigen specific Treg therapy (Ovasave) began but terminated 
early (NCT02327221). The early termination of this study was reportedly due to 
manufacturing difficulties and the trial is to recommence recruitment 
(https://www.biopharma-reporter.com/Article/2016/05/27). 
The therapeutic potential of this cell population may extend beyond quashing 
inflammation to hindering colitis-associated colon cancer, making further study of these 
populations paramount.35 
 
Immunoregulatory B-Cells 
B cells are an integral part of the adaptive immune system that produce antibodies, 
secrete cytokines, and can also communicate with other cells including Tregs to maintain gut 
homeostasis,.36 In humans, therapies that target B-cells, for example rituximab, are not 
effective in IBD and can clinically exacerbate, or even induce colitis.37 This observation affirms 
an important, protective role of B-cells in maintaining intestinal homeostasis.  
In recent years, interest has grown around a ‘regulatory’ phenotype that can secrete 
IL-10, IL-35 and transforming growth factor (TGF)-β to maintain peripheral tolerance.38 In this 
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review, IL-33 and IL-35 are latter discussed as anti-inflammatory cytokines with a therapeutic 
potential worth exploiting for therapeutic gain. IL-10-producing B cells are present in the 
gastrointestinal mucosa of patients with active Crohn’s disease and ulcerative colitis 
compared to healthy controls.39  
Sattler and colleagues reported that intraperitoneal IL-33 injection into IL10-/- mice 
exacerbated colitis whereas IL-33-treated wildtype mice (with intact IL-10 receptors) didn’t 
develop colitis.40 Upon investigating the underlying mechanism, there was no change in the 
frequency of CD25+ or Foxp3+ Tregs, but increased IL-10 producing B cells (BregIL-33) in 
wildtype, but not IL10-/- mice. Adoptive transfer of these BIL-33 cells transferred into IL-10-/- 
mice led to histological and clinical improvements in colitis. Taken together, this important 
study suggests that IL-10 deficiency reduces the function of this immunoregulatory cell 
population. 
In support of these findings, intravenous adoptive transfer of peritoneal cells into mice 
with DSS-induced colitis improved disease activity scores, mucosal recovery and survival 
rates.41 The mechanism is likely through dual activity of IL-10 and TGF-β secreted by natural 
regulatory B cells (and also macrophages).41 Adoptive transfer of these immunoregulatory B 
cells may therefore be an attractive treatment in the future but this needs further assessment 
in pre-clinical models of IBD alongside a greater understanding of the biological function of 
the cells in the human gastrointestinal tract.  
 
Tolerogenic Dendritic Cells 
Dendritic cells are professional antigen presenting cells that induce immune tolerance 
within the gastrointestinal mucosa to luminal contents.42  
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The mechanisms that underlie the anti-inflammatory role of dendritic cells is not fully 
defined. Their influence over pro-inflammatory T-cells and Treg development is likely vital to 
protective functions. For example, CD103+ dendritic cells isolated from mesenteric lymph 
nodes can induce the differentiation of naïve CD4+ T-cells into Foxp3+ Tregs.43 CD103+ 
dendritic cells are downregulated during experimental colitis and produce thymic stromal 
lymphopoietin in response to TLR activation, which suppresses the secretion of IL-17 from T-
cells and promotes Foxp3+ Treg development.44 In human IBD, patients with Crohn’s disease 
have more CD103+ lymphocytes in their lamina propria compared to patients with ulcerative 
colitis or healthy controls.45  
The anti-inflammatory capabilities of CD103+ dendritic cells are reduced in murine 
colitis models.46 The ability of CD103+ dendritic cells to promote the development of Foxp3+ 
Tregs is significantly impaired in T-cell induced colitis in RAG-/- mice and, instead, CD103+ 
dendritic cells appear to favour the development of interferon-γ-producing CD4+ T-cells in the 
inflammatory microenvironment.46 This is discouraging when considering the application of 
dendritic cells as cell therapy for IBD. Nonetheless, there have been some encouraging data. 
Vasoactive intestinal peptide-induced dendritic cells can induce Tregs, which show a 
protective and therapeutic value in trinitrobenzene sulfonic acid (TNBS)-induced murine 
colitis.47 Granulocyte-Colony Stimulating Factor (G-CSF) induces IL-10-secreting T-cells in the 
peripheral blood, as well as plasmacytoid dendritic cells in the lamina propria in human 
Crohn’s disease patients who clinically respond to G-CSF therapy.48  
Colonic microbiota play a role in the pathogenesis of IBD.1 These bacteria impact on 
mucosal dendritic cell function, and there is evidence that this interaction can lead to 
promotion of immunoregulatory mechanisms including oral tolerance.49 CD103+CD11b+ 
dendritic cells can recognise flagellin in the lamina propria and upregulate IL-23 which induces 
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epithelial cells to express RegIII-γ, a bactericidal c-type lectin, in response to TLR-5 
activation.50 Mice treated with caecal bacterial antigen-pulsed regulatory dendritic cells 
secrete high levels of IL-10 and ameliorate colitis in T-cell transfer-induced murine colitis.51 In 
the same study, regulatory dendritic cells also induced the differentiation of naive CD4+ T-
cells into CD4+CD25+Foxp3+ T-cells in vitro and in vivo. These findings support the growing 
hypothesis that the gut microbiota can shape dendritic cell populations. The question is 
whether this can be targeted for therapeutic gain in IBD.  
In keeping with this hypothesis, Bifidobacterium infantis increases CD103+ and retinoic 
acid metabolising dendritic cells that induce Foxp3+ Tregs and suppress Th17 cells.52 This 
partially explains why Bifidobacterium infantis can suppress IL-17 production in DSS-induced 
murine colitis and induce IL-10 in vitro.53 Taken together, it would appear that adoptively 
transferred tolerogenic dendritic cells could prove therapeutically beneficial for IBD and this 
continues to be explored in pre-clinical models. However, it is clear that dendritic cell 
plasticity and function in the gastrointestinal mucosa is complex with conflicting data and 
further work will be required to translate to human disease. In a single-centre, phase 1 trial, 
9 patients with treatment-refractory Crohn’s disease were treated with autologous transfer 
of tolerogenic dendritic cells. These cells were derived from blood monocytes in vitro and 
delivered by ultrasound guided intra-peritoneal injection. The treatment was well-tolerated, 
induced remission in 1 patient and a showed good clinical response in 2 patients.54 Additional 
clinical trials of this therapy are recruiting (Intralesional Tolerogenic Dendritic cells in Crohn’s 
Disease Treatment (TolDecCDintra), NCT02622763). 
Further mechanistic studies are required to better understand dendritic cell biology in 
the gastrointestinal tract and identify the target patient population most likely to benefit from 
this cell therapy. 
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Innate Lymphoid Cells 
Innate lymphoid cells (ILC) are a recently discovered population of immune cells.55 ILCs 
are sub-classified into type 1, type 2 and type 3, based on transcription factor association, cell 
surface marker expression and cytokine response.55 Unlike T-cells and B-cells ILCs do not 
express recombined antigen-specific receptors.56 The biology of ILCs has been summarised 
elsewhere.55–57 In summary, group 1 ILCs constitutively express transcription factor T-bet and 
are activated in response to IL-12 and IL-18. They secrete type 1 cytokines including 
interferon-γ. Their key role is to promote immunity to intracellular bacteria, viruses and 
parasites. Group 2 ILCs express GATA3 and ROR-α and are activated in response to alarmins 
such as IL-25, IL-33 and thymic stromal lymphopoietin. They secrete type 2 cytokines including 
IL-4, IL-5 and IL-13. Their key role is to promote immunity to helminths. Group 3 ILCs 
constitutively express ROR-γt and are activated in response to IL-23, IL-1α and IL-1β. They 
secrete IL-17, and IL-22. Their key role is to promote immunity to extracellular bacteria, 
especially to maintain tolerance to commensal gut microbiota.  
In IBD, patients with Crohn’s disease have an increased expression of intraepithelial 
type 1 ILCs within the colonic mucosa.58 These cells produce interferon-γ and worsen colitis 
in anti-CD40-induced murine colitis, so may be contributing to disease pathogenesis.58 
Suppressing the expression and function of such cells may be therapeutically advantageous. 
Group 3 ILCs play a role in maintaining intestinal homeostasis and could be a promising 
cellular target. Specifically, a subset termed IL-22 producing NCR+ (CD56NKp44) group 3 ILCs, 
make up around 5% of normal colonic lymphocytes, resist mucosal infection and promote 
epithelial barrier integrity.59 Although present in small numbers relative to other 
lymphocytes, ILCs exert a potent effect on immune responses.60 The NCR+ subtype confers 
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protection in DSS-induced and T-cell transfer murine colitis, through increased secretion of 
IL-22 resulting from retinoic acid signaling61 or expression of aryl hydrocarbon receptor 
(essential for the maintenance and function of type 3 innate lymphoid cells).62 
The emergence of this new cell type with a key role in the arena of gastrointestinal 
mucosal immunity offers a potential new therapeutic target in IBD. However, a significant 
amount of pre-clinical investigation and a better characterisation of their role in the human 
GI tract in health and disease is required before translational studies can be considered and 
developed. Caution is warranted as ILCs are central to the development of inflammation 
associated colonic cancer through IL-22 stimulation of epithelial cell proliferation.63 
 
ANTI-INFLAMMATORY CYTOKINES 
IL-10 
Therapeutically enhancing interleukin (IL)-10, the quintessential anti-inflammatory cytokine, 
showed promising efficacy in pre-clinical models of IBD, but unfortunately human trials to 
date have failed to show a direct translational benefit in human patients.64 This is likely to 
reflect the differences in biology from murine models to human disease alongside 
considerations in patient recruitment, disease characterisation and cytokine delivery. As such, 
there still is interest at progressing this therapeutic strategy forward. For example, a phase 1 
double-blind randomised control trial to assess safety, tolerability and pharmacology of IL-10 
was commenced, but prematurely terminated in 2016 due to potential risk of further dosing 
in healthy subjects (NCT02711462). Currently, a phase 2a double-blind randomised control 
trial is underway to assess IL-10 as an add-on therapy to infliximab in patients with active 
ulcerative colitis (NCT03269695).  
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Back in the laboratory, success of pre-clinical studies have fuelled the race to identify 
novel anti-inflammatory cytokines with translational capability to bolster the 
immunoregulatory capacity of the immune system to sequester inflammation, often by 
indirectly upregulating IL-10.  
 
IL-27 
The known biology of IL-27 has recently been reviewed.65 In brief, interleukin-27 (IL-
27) is a heterodimeric type-1 cytokine expressed by many cell types including dendritic cells, 
macrophages, plasma cells, epithelial cells and endothelial cells. IL-27 is composed of Epstein-
Barr virus-induced gene 3 and p28 subunits, and the IL-27 receptor is composed of two 
subunits, namely gp130 and IL27Rα. Upon receptor binding, Janus Kinase/STAT, PI3K/Akt or 
MAPK signalling pathways are activated. This results in phosphorylation of STAT1, STAT3, 
STAT5 and STAT6. The best known downstream effects of IL-27 involve regulating T-cell 
responses (for example, inhibition of the  lineage commitment of Th17 cells by blocking 
retinoic acid receptor-related orphan receptor (ROR)-γt, preventing Fas-mediated activation-
induced cell death, and inhibiting Th2 differentiation and cytokine expression through 
increasing T-bet and suppressing GATA-3 expression) and inducing IL-10 production from Tr1 
T regulatory cells.  
An observational, cross-sectional study of 54 IBD patients reported that IL-27 mRNA 
is increased in patients with active Crohn’s disease compared to inactive disease with higher 
mucosal IL-27 protein expression in patients with active ulcerative colitis, compared to tissue 
controls or active Crohn’s disease.66 The biological consequences of this expression profile in 
the inflamed mucosa is unclear, although a protective effect is suspected through 
extrapolation of IL-27 mediated immunosuppressive capabilities.65  
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There have been several murine studies investigating the role of IL-27 in different 
colitis models. In T-cell transfer models, IL-27 is essential for enhancing Treg function and 
enabling IL-10 secreting B-cells to attenuate colitis.67,68 In DSS models, colitis is more severe 
and survival reduced in IL-27-R-/- mice.69 IL27-R-/- in RAG-/- mice also suffer more severe colitis 
compared to RAG-/- mice with intact IL-27 receptors.69 Hanson and colleagues demonstrated 
that mucosal delivery of IL-27, by a Lactococcus lactis bacterial vector, is therapeutically 
beneficial in both T-cell transfer and DSS models of murine colitis, and is dependent upon 
increased IL-10 production by T-cells in the gastrointestinal mucosa.70 Mucosally delivered IL-
27 attenuated innate cell driven acute murine colitis through IL-10 dependent, T cell 
independent mechanisms including inhibition of chemokine gradient and neutrophil 
infiltration.71 These data suggest that IL-27 promotes immunosuppression through IL-10 
amplification. However, neutralisation of IL-27 worsens colitis in IL-10-/- mice indicating other 
mechanisms are also important.72 Furthermore, IL-27 can suppress Th17 and Th1 
differentiation independent of IL-10.72 Treating murine colitis (induced by both TNBS and DSS) 
with single-chain human IL-27, delivered by subcutaneous osmotic pumps, clinically improves 
colitis through suppression of IL-17 producing T-helper cells.73 Therefore, IL-27 appears 
capable of attenuating colitis by IL-10 dependent and independent mechanisms.  
However, there is conflicting murine data in the literature that require further 
consideration. It has been reported that IL-27 promotes colitis, enhancing IL-6 and IL-1β 
production and promoting Th17 differentiation; loss of IL27Rα has been associated with 
clinical improvements in murine colitis models.74  
Most of this data arises from preclinical models. The role of IL-27 in human IBD 
requires characterisation before IL-27 directed therapy for IBD can be further explored in the 
clinical arena.  
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IL-33 
Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines and is constitutively 
expressed in the nucleus of most epithelial, endothelial and stromal cells where it regulates 
gene expression through stability of chromatin structure.75 IL-33 can sequester NF-κB to 
dampen pro-inflammatory responses and can be released into the extracellular environment 
to function as an ‘alarmin’ or damage associated molecular pattern.75 Immune cells can 
actively secrete IL-33 in response to pro-inflammatory cytokines such as TNF, IL-1β, IL-3 and 
IL-4.75 Given the complexities of pro- versus anti-inflammatory effects, the role of IL-33 in IBD 
remains unclear. Again, most data have been derived from pre-clinical models of IBD and the 
translational impact of this to the human disease is not yet defined. 
In the gastrointestinal tract, from an anti-inflammatory perspective, IL-33 and its 
receptor ST2 are expressed on colonic Tregs.76 IL-33 promotes TGF-β1-medited Treg 
differentiation and the accumulation of Tregs in an inflammatory environment.76 IL-33 
promotes IgA production (important for maintaining gut-microbial homeostasis) and 
prevents IL-1α-dependent colitis and colitis-associated colon cancer.77 Intraperitoneal-
delivered recombinant IL-33 in DSS-induced murine colitis clinically, macroscopically and 
histologically improves inflammation through reducing Th17 and Th1 cell populations in the 
lamina propria, effectively switching from a Th1 to Th2-mediated response.78 Conversely, IL-
33 can drive eosinophilic infiltration and potent mucosal adaptive immune responses which 
lead to chronic ileitis.79 Genetic ablation of, or monoclonal antibodies against, ST2 can 
significantly improve colitis in murine models. Administration of IL-33 has also been shown to 
increase intestinal permeability.80  
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Is there any information from human studies? In a large paediatric and adult patient 
cohort, Latiano and colleagues reported that single nucleotide polymorphisms in the IL-33 
gene (such as rs3939286) are associated with IBD susceptibility.81 Paediatric carriers of the IL-
33 polymorphism were 44% more likely to respond to steroids compared to those who did 
not carry the risk allele. Adult patients carrying the risk allele were more likely to have 
extensive, severe disease. Patients with IBD also had increased IL-33 mRNA expression in 
inflamed mucosa.81 Studies have confirmed a significant relationship between increased IL-
33 expression, increased severity of disease and ulcerative colitis disease phenotype and, 
similar to IL-33, ST2 expression is increased in the intestinal mucosa in patients with UC and 
is positively associated with disease activity: ST2 has been proposed as an activity biomarker 
for predicting clinical outcomes in UC.82,83  
Although we know IL-33 is increased in human IBD, the biological consequence of this 
is unclear. It would appear that IL-33 plays an important role in IBD pathogenesis, although 
the underlying mechanisms are not yet characterised in vivo.  
 
IL-35 and IL-37 
Interleukin 35 (IL-35) and interleukin 37 (IL-37) are two recently discovered cytokines 
whose anti-inflammatory properties have attracted interest in IBD. IL-35 is a member of the 
IL-12 family and is produced by CD4+Foxp3+ Tregs, activated B-cells and likely tolerogenic 
dendritic cells. IL-35 regulates IL-10 producing B cells and suppresses Th17 responses in 
vitro.84 IL-37 is a member of the IL-1 cytokine family and, although cytokines in this family 
tend to be pro-inflammatory, IL-37 can function as part of a negative feedback mechanism to 
limit inflammation in an IL-10-independent fashion.85 
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Gene and protein expression of IL-35 is higher in colonic mucosa from adult patients 
with IBD, compared to healthy controls.86 IL-37 expression in infiltrating immune cells and 
intestinal epithelial cells is also increased.87 Although reduced levels of the cytokines 
themselves have been reported in the peripheral blood of IBD patients compared to healthy 
controls,86 other studies reveal an increased presence of circulating IL-35-expressing CD4+ and 
CD8+ T-cells, and increased IL-37-producing CD14+ monocytes, -CD56+ natural killer cells and 
-CD19+ B-cells in patients with IBD, compared to healthy controls or patients with inactive 
disease.39 
Gene expression of major splice variant IL-37b is increased in the inflamed mucosa in 
patients with ulcerative colitis and Crohn’s disease, and is undetectable in normal colonic 
mucosa.88 Expression is predominantly in the epithelia and infiltrating immune cells of the 
inflamed mucosa.89 The consequence of this is not clear but a clue may come from a study 
where IL-37b gene transfer enhanced the therapeutic effects of mesenchymal stromal cells 
in the resolution of DSS-induced murine colitis.89 In DSS-induced colitis in a transgenic mouse 
expressing human IL-37 under a CMV promoter, IL-37 expression was only detectable in the 
colon when the epithelial barrier had been disrupted.90 Although IL-37 increases IL-10, the 
protective effects of IL-37 do not disappear upon blocking IL-10R in IL-37 transgenic mice – 
the protective effects are not dependent upon IL-10 production and are yet uncharacterised.  
There is limited data on the biological function of IL-35 in the gastrointestinal tract. 
Collison and colleagues reported that IL-35 can induce the generation of a unique 
subpopulation of Tregs, - IL-35 producing Tregs - in vitro and in vivo, that can function 
independent of IL-10 and TGF-β.91 Both IL-35 and IL-27 belong to the IL-12 family of 
heterodimeric cytokines, share the Epstein-Barr virus induced gene protein 3 subunit, and are 
upregulated in IBD.65,84 In this regard, Wirtz and colleagues investigated the differential role 
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of these two cytokines through DSS-induced colitis, TNBS-induced colitis, T-cell transfer and 
spontaneous colitis models in IL-27p28-/- and EB13-/- mice.92 The study found IL-27p28 (the 
unique subunit of IL-27)-deficient mice were similar to wild-type mice whereas Epstein-Barr 
virus induced gene protein 3 (shared subunit)-deficient mice developed severe or worsened 
colitis, with decreased survival. In addition, the administration of single chain IL-35 prevented 
the development of colitis through suppressing Th1 and Th17 responses.92 
IL-37 and IL-35 thus offer promising therapeutic potential in modulating inflammation 
in IBD, independent of IL-10. Again, the role of these cytokines in human IBD requires 
characterisation before the therapeutic potential can be fully understood. Perhaps these 
cytokines will offer the greatest efficacy in patients with an IL-10 high expression phenotype.  
 
ENDOGENOUS MOLECULAR TARGETS TO REGULATE IMMUNE RESPONSES 
miRNA 
A micro RNA (miRNA) is a small, single-stranded, non-coding, hairpin ribonucleic acid 
(RNA) approximately 22 nucleotides long. Transcribed miRNA binds to a specific mRNA and 
induces its degradation. One of the first microarray-based studies in this field found that 
patients with ulcerative colitis had a differential expression of miRNAs, distinct from those 
expressed in patients with irritable bowel syndrome, Crohn’s disease, microscopic colitis or 
infectious colitis.93 There was also differential expression of miRNAs in patients with active 
ulcerative colitis compared to latent disease. Specifically, miRNA-192 was reduced during 
active ulcerative colitis. Subsequently, a differential expression of miRNA between ileal and 
colonic Crohn’s disease has been reported.94 This endogenous method of post-
transcriptional gene regulation is therefore of interest in IBD pathogenesis and possibly 
highlights an opportunity to finely tune inflammatory activity. 
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miR-192 targets the chemokine macrophage-inflammatory peptide 2α, which 
increases the migration of neutrophils and lymphocytes to the intestinal mucosa.93 miR-141 
can suppress expression of the chemokine CXCL12β and thus CXCL12β-mediated T-cell, 
neutrophil and macrophage migration to the inflamed gut.95 Therapeutic upregulation of 
miRNA-141 in TNBS-induced murine colitis reduces leukocyte recruitment to inflamed 
intestinal mucosa.95 miR-146 is upregulated upon TLR activation and targets the IL-1 receptor 
associated kinase and TNF receptor-associated factor 6, upstream of NF-κB, to limit 
inflammation in a negative feedback fashion.96  
Upregulation of certain miRNAs may limit inflammation. For example, miR-155 is 
thought essential for Treg development and, whilst insufficient to independently control Treg 
function, it can augment other miRNAs in doing so.97 
miR-10a suppresses Th17 and Th1 responses and downregulates the expression of IL-
12/IL-23p40 and NOD2 on dendritic cells. This reduces the secretion of IL-12 and IL-23.98 
Interestingly, miRNA-10a is decreased in the inflamed colonic mucosa and peripheral blood 
mononuclear cells in patients with IBD, and is later upregulated following anti-TNF-α 
treatment.98 This observation may partly explain the therapeutic mechanism of anti-TNF 
biologic therapy.  
NOD2 plays a critical role in modulating a protective inflammatory response and in 
maintaining intestinal homeostasis.99 NOD2 polymorphisms in Crohn’s disease commonly 
lead to epithelial barrier dysfunction, chronic inflammation and likely impact microbial 
dysbiosis.99 miR-146a is a nitrous oxide-triggered, downstream messenger of NOD2 signalling 
that promotes pro-inflammatory responses, through sonic hedgehog signalling, and 
expression of the transcription factor NUMB.100 miRNA-192, 495, 512 and 671 were found to 
decrease NOD2, downregulate NF-κB and inhibit IL-8 and CXCL3 mRNA in colonic epithelial 
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HCT116 cells.101 However, miR-192 was not associated with NOD2 regulation in a paediatric 
cohort.102 Nonetheless, further characterisation is required and miRNA may be a therapeutic 
target for patients with NOD2 mutation phenotypes of IBD.  
miRNAs also offer an opportunity to therapeutically target the intestinal epithelium 
directly. In human ulcerative colitis and DSS-induced murine colitis, miR-150 targets the 
transcription factor c-Myb which, leads to decreased apoptosis,103 suggesting that 
upregulation of miR-150 may be therapeutic to protect the epithelial barrier.  
miRNAs with a pro-inflammatory role also exist, including miRNA-301a which 
increases TNF-α production and Th17 cell differentiation.104 In these circumstances, an anti-
sense miRNA may have therapeutic benefit. Proposed RNA interference targets are 
summarised in Table 1.  
Clinical studies exploring this treatment strategy are lacking for now. A phase 1 trial 
examining miRNA-RX34 in liver cancer was prematurely terminated after 5 immune-related 
serious events were reported (NCT01829971). A better understanding of the clinical safety 
and utility, along with identification of miRNAs that upregulate immunosuppressive host 
responses, will be of future interest as a novel future therapy in IBD. 
 
Oligonucleotides 
 An oligonucleotide describes a short, synthetic DNA or RNA molecule. The therapeutic 
rationale is similar to miRNA – mucosal delivery binds to target nucleotide sequences and 
stimulates or inhibits effector pathway gene expression. The most successful studies to date 
using this strategy in IBD have exploited the TGFβ pathway. TGFβ is a multi-functional 
cytokine with immunosuppressive effects, produced by many immune and non-immune 
cells.105 TGFβ is important in controlling many cellular functions, including proliferation, 
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differentiation, cell-cycle regulation, wound healing and angiogenesis. Loss of the TGFβ-
signalling pathway is associated with IBD.106,107 The endogenous regulatory protein SMAD7 
blocks TGFβ-mediated inhibition of NF-κB, through activating NF-κB inhibitor-α.108,109 In 
Crohn’s disease, TGFβ signalling is inhibited by high levels of SMAD7 protein, resulting in 
unregulated production of pro-inflammatory cytokines.109 Anti-sense SMAD7 oligonucleotide 
(Mongersen) has been developed as a therapeutic agent for use in IBD, blocking mRNA of 
SMAD7, inhibiting protein production and removing mucosal presence of this endogenous 
regulator of TGFβ signalling. Mongersen appeared safe and capable of improving endoscopic 
and clinical markers of colitis, as well as inducing remission in patients with active Crohn’s 
disease in Phase II trials.109–111 Following this, a phase 3 double-blind randomised control trial 
commenced, investigating the efficacy of Mongersen as a maintenance therapy in Crohn’s 
disease (NCT02641392). However, this was prematurely discontinued based on lack of 
emerging benefit and further developments are awaited.  
 Toll-like receptor 9 (TLR9) is expressed in numerous antigen presenting cells including 
dendritic cells, B-cells and macrophages.112 Activation of TLR9 occurs upon binding of 
cytosine-guanine nucleotide sequences present on microbial DNA fragments and synthetic 
oligonucleotides. In intestinal epithelial cells, if the apical surface is stimulated, the non-
canonical NF-κB pathway is activated, resulting in release of anti-inflammatory molecules 
such as IL-10.113–115 In the laboratory, the anti-microbial peptide cathelicidin and synthetic 
oligonucleotides are capable of inducing this pathway.116 While both show translational 
potential, human studies concentrate on synthetic oligonucleotides. A double-blind placebo-
controlled randomised control trial of a TLR9 agonist in 131 patients with moderate to severe 
ulcerative colitis was performed.114 While not sufficient to induce clinical remission compared 
with placebo, TLR9 oligonucleotide DIMS0150 induced symptomatic remission, mucosal 
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healing and histological improvement in colitis at 4 weeks. A previous open-label phase 2a 
trial showed that, of the 22 patients enrolled, oral administration of TLR9 oligonucleotide BL-
7040 induced remission in 2 patients and mucosal healing in 8 patients. Mucosal neutrophil 
and IL-6 levels were also reduced.115 While these findings are modest, additional trials are 
required.  
Therefore, oligonucleotides can inhibit (SMAD7) or stimulate (TLR9) critical pathways 
to bolster immunoregulatory capability for therapeutic gain in IBD.   
 
The Endocannabinoid System 
This system involves multiple endogenous ligands, enzymes and molecules 
responsible for, cannabinoid biosynthesis and cellular uptake.117 ∆9-tetrahydrocannabinol 
signals through two G-protein coupled cannabinoid receptors, namely CB1 and CB2.  
CB1 and CB2 signalling pathways reduce intestinal inflammation.117 Inflammation can 
upregulate endogenous cannabinoid levels which impact intestinal motility. Although both 
receptors seem to be important, they are differentially expressed in both normal and 
inflamed intestinal mucosa.118,119 In healthy colon, CB1 receptors are expressed on the 
epithelium, smooth muscle and submucosal myenteric plexus where they contribute to 
wound healing. Both CB1 and CB2 receptors are expressed on plasma cells in the lamina 
propria. In IBD, patients have increased expression of colonic epithelial CB2 receptors.118 CB2 
receptors are expressed on macrophages and the immune cell infiltrate during colitis whereas 
CB1 receptors are upregulated in enteric neurons and endothelium.118–120 Clearly, regulating 
intestinal motility is not the only important function of this system, there is also 
immunoregulatory capability.  
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CB2 agonists can ameliorate cytokine-mediated colonic inflammation in explant 
tissue, without affecting epithelial permeability.121 They can also reduce reactive oxidative 
species production within intestinal epithelial cells and ameliorate murine experimental 
colitis.122 Central cannabinoid receptors have a greater intestinal anti-inflammatory effect 
compared to peripheral receptors.123  
CB2 agonism could be a new therapeutic direction for IBD. Activation of the CB2 
receptor doesn’t trigger the psychotropic side effects associated with cannabinoids, making 
this a clinically attractive therapeutic target.124  
There are several ways to bolster the endogenous endocannabinoid system including 
promoting biosynthetic enzymes and inhibiting CB1 and CB2 ligand degradation pathways. 
For example, blocking cellular uptake and intracellular degradation pathways through VDM11 
(an endocannabinoid membrane transport inhibitor), a fatty acid amide hydrolase inhibitor, 
or a combination of these reduces intestinal inflammation through increasing the 
concentration of anandamide, a fatty-acid neurotransmitter degraded by fatty acid amide 
hydrolase inhibitors.125,126  
N-acylethanolamine-hydrolysing acid amidase inhibitors increase an endogenous anti-
inflammatory fatty acid known as N-palmitoylethanolamine. N-palmitoylethanolamine has a 
high affinity for the endocannabinoid receptors and can subsequently reduce colonic 
inflammation and improve colitis through targeting the S100B/TLR-4 axis on enteric glial cells, 
reducing the downstream inflammatory effects of NF- κB.127 Enteric glial cells are astrocyte-
like cells found in enteric ganglia of the submucosal and myenteric plexus that promote 
epithelial barrier repair.128 Glial regulation of epithelial barrier function can become disrupted 
in IBD and cannabidiol has been shown to restore glial-immune homeostasis to ameliorate 
inflammation.129 This therapeutic strategy is summarised in Figure 1.  
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Translating endocannabinoid in vitro and in vivo studies into clinical practice is 
controversial given associations with cannabis misuse. The efficacy of cannabis cigarettes on 
patients with treatment-refractory Crohn’s disease has been assessed in a small randomised 
trial and did not induce remission.130 A more recent randomised control trial of oral canabidiol 
was safe in Crohn’s disease, but with no statistical efficacy demonstrated.131 A double-blind 
randomised control trial of 36 patients with Crohn’s disease is planned for July 2018 to 
determine whether oral cannabidiol is a safe and effective adjunct therapy for symptomatic 
relief in Crohn’s disease (NCT03467620). The intestinal endocannabinoid system offers 
promise as a therapeutic target in IBD.  
 
WHERE DO WE GO FROM HERE? 
Our understanding of the immune system has advanced considerably over the past 
few years, providing insight into ways we may be able to harness its endogenous checks and 
balances for therapeutic gain (Figure 2). However, these mechanisms are complex and 
potential adverse effects must be considered.  
There are several novel treatments to bolster the endogenous anti-inflammatory 
activity close to or recruiting to clinical trials currently and these agents may enter the future 
therapeutic arena for IBD if shown to be efficacious with a satisfactory side effect profile.  
In addition, there are other novel strategies to treat IBD emerging that may exert 
effect through partial enhancement of the endogenous immunosuppressive mechanisms and 
not discussed here. An example of this is mesenchymal stem cell therapy that is mainly 
immunosuppressive through inhibition of many pro-inflammatory cells types, such as 
dendritic cells, B cells, effector T cells and NK cells. They also act however to promote Treg 
and immunoregulatory macrophage subsets, enhancing immunosuppressive capability.132 
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There is significant variability at an individual patient level in IBD disease activity, 
progression over time and response to treatment. Better characterisation of disease 
phenotypes will better inform research and treatment decisions in the era of personalised 
medicine.  
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Table 1: miRNA manipulation for therapeutic consideration. 
miRNA Proposed Direction of 
modulation 
Potential Therapeutic Effect 
miR-192 Increase Decreases migration of neutrophils and 
lymphocytes to the intestinal mucosa 
miR-141 Increase Reduce CXCL12β-mediated T-cell, neutrophil 
and macrophage migration to the inflamed 
bowel 
miR-146 Increase Reduce inflammation, downstream of IL-1 
receptor, through blocking NF-kB pathway 
miR-146a Decrease Decrease inflammation downstream of 
NOD2 
miR-155 Increase Promote Treg function 
miR-10a Increase Reduced inflammation by suppressing Th17 
and Th1 responses and secretion of IL-12 and 
IL-23 
miR-192 
miR-495 
miR-512 
miR-671 
Increase Downregulate NF-κB and inhibit IL-8 and 
CXCL3 
miR-150 Increase Decreases apoptosis 
miR-301a Decrease Reduce TNF-a production and Th17 cell 
differentiation  
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FIGURE LEGENDS  
 
Figure 1 - Targeting the endocannabinoid system in IBD. A - In the non-inflamed colon, CB1 
is expressed on colonic epithelial cells, smooth muscle cells and the submucosal myenteric 
plexus. CB1 and CB2 are expressed on plasma cells in the lamina propria. B – In IBD, CB1 is 
upregulated on enteric neurons and endothelium whereas CB2 is expressed on the 
inflammatory cell infiltrate and is upregulated on colonic epithelial cells. C - CB1 and CB2 
ligand degradation pathways can be inhibit by VDM11 or a fatty acid amide hydrolase 
inhibitor which increases the concentration of anandamide, which helps ameliorate 
inflammation in the gut. N-palmitoylethanolamine can also inhibit inflammation by 
sequestering NF- kB by targeting the S100B/TLR-4 axis on enteric glial cells.  
 
Figure 2 - Strategies to promote endogenous immune-mediated anti-inflammatory activity  
in IBD. 
 


